Botanical and Plant-Derived Drugs: Global Markets

Botanical and Plant-Derived Drugs: Global Markets published by BCC Research in February, 2009. This report consists of 130 pages and the price starts from US $ 4850.

Introduction

Abstract

This report:

• Identifies and classifies the plant-derived drugs that have been commercialized to date
• Contains forecasts for the global volume and value of plant-derived drug shipments and their markets through 2013
• Analyzes the historical and current volume and value of shipments of each of these drugs in specified geographical markets
• Identifies and evaluates the impact of factors that will drive future demand for plant-derived drugs
• Describes plant-derived drugs that are currently in the clinical testing or approvals stage and assesses the probability that they will be commercialized successfully in the next 5 years
• Profiles the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years.

Table of Contents

Chapter-1: SUMMARY 4

• SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS) 7
• SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS) 8
• SUMMARY (CONTINUED) 9
• SUMMARY (CONTINUED) 10

Chapter-2: OVERVIEW 32

• BRIEF HISTORY OF PLANT-DERIVED MEDICINES 11
• BRIEF HISTORY OF PLANT-... (CONTINUED) 12
  • TABLE 2 KEY DATES IN BOTANICAL MEDICINE 13
  • TABLE 3 WELL KNOWN PLANT-DERIVED DRUGS 13
• OPPORTUNITY LIES BEYOND WHAT' S KNOWN 13
• OPPORTUNITY LIES BEYOND ... (CONTINUED) 14
  • FIGURE 1 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000 - 2005) (%) 15
• KEY DRIVERS 16
• KEY CHALLENGES 16
• SIGNS OF INDUSTRY INVESTMENT 17
  • TABLE 4 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT 18
  • TABLE 5 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS 19
  • TABLE 5 (CONTINUED) 20
• BOTANICAL DRUGS DEFINED 20
• UNDERSTANDING THE REGULATORY PROCESS 21
• UNDERSTANDING THE REGULATORY ... (CONTINUED) 22
  • TABLE 6 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY 23
• THE FIRST APPROVED BOTANICAL 23
• A GROWING PIPELINE 24
  • FIGURE 2 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER) 25
• OVERALL PHARMA LANDSCAPE 26
• OVERALL PHARMA LANDSCAPE (CONTINUED) 27
  • TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS) 28
• MAJOR CLASSES OF PLANT DRUGS 28
  • Terpenes and Steroids 29
  • Terpenes 29
  • Steroids 29
  • Alkaloids and Glycosides 30
  • Alkaloids 30
  • Ergot Alkaloids 31
  • Morphine Alkaloids 31
  • Vinca Alkaloids 31
  • Glycosides 31
  • Cardiac Glycosides 32
  • Anthraglycosides 32
  • Phenols 32
  • E. Cava Algae 32
  • Flavonoids 32
  • Resveratrol 33
  • Coumarin 33
  • Catechins 33
  • Proanthocyanidins 33
• INTELLECTUAL PROPERTY 34
• PRODUCTION 35
• PRODUCTION (CONTINUED) 36
• MOVING PRODUCTION FORWARD 37
• ARTEMISININ: A CASE STUDY 38
• SUPPLY AND LEGAL ISSUES 39
  • TABLE 8 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS 40
• DRUG DEVELOPMENT AND MANUFACTURE 40
• Drug Development ... (Continued) 41
  • TABLE 9 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES 42

Chapter-3: MARKET SEGMENTATION 6

• GEOGRAPHIC SEGMENTATION 43
• SALES OF PLANT-DERIVED DRUGS BY REGION 43
  • TABLE 10 PLANT-DERIVED DRUG SALES FORECAST BY REGION, THROUGH 2013 (% TOTAL SALES) 43
  • FIGURE 3 GEOGRAPHIC SEGMENTATION FOR PLANT-DERIVED DRUGS, 2008 AND 2013 (%) 44
• THERAPEUTIC AREA SEGMENTATION 45
• NUMBER OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA 45
  • TABLE 11 FDA APPROVED BOTANICAL DRUGS FORECAST THROUGH 2013 (UNITS) 45
  • FIGURE 4 COMPOSITION OF FDA APPROVED BOTANICAL INDICATION FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%) 46
• Value of Plant-Derived Drugs by Therapeutic Area 47
  • TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPUETIC AREA, THROUGH 2013 ($ MILLIONS) 47
  • FIGURE 5 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%) 48

Chapter-4: THERAPEUTIC AREAS IN DETAIL FOR PLANT-DERIVED AND BOTANICAL DRUGS, THROUGH 2013 30

• HORMONE THERAPY AND METABOLISM APPLICATIONS 49
  • TABLE 13 PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATE STAGE DEVELOPMENT 50
• INFECTIOUS DISEASE APPLICATIONS 50
• INFECTIOUS DISEASE ... (CONTINUED) 51
  • TABLE 14 PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENT 52
  • TABLE 14 (CONTINUED) 53
  • TABLE 14 (CONTINUED) 54
  • TABLE 14 (CONTINUED) 55
• PAIN AND CENTRAL NERVOUS SYSTEM DISEASE APPLICATIONS 56
  • TABLE 15 BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGS 57
  • TABLE 16 PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENT 57
  • TABLE 16 (CONTINUED) 58
  • TABLE 16 (CONTINUED) 59
  • TABLE 16 (CONTINUED) 60
• CARDIOVASCULAR AND METABOLIC DISEASE 60
  • TABLE 17 PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGE DEVELOPMENT 61
• RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE 62
  • TABLE 18 PLANT-DERIVED RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENT 63
  • TABLE 18 (CONTINUED) 64
• DERMATOLOGY APPLICATIONS 64
  • TABLE 19 PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGE DEVELOPMENT 65
  • TABLE 19 (CONTINUED) 66
• GASTROINTESTINAL APPLICATIONS 66
  • TABLE 20 PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE DEVELOPMENT 66
  • TABLE 20 (CONTINUED) 67
• ONCOLOGY APPLICATIONS 67
  • TABLE 21 ESTIMATED U.S. CANCER CASES, 2007 67
  • TABLE 21 (CONTINUED) 68
  • TABLE 22 PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENT 69
  • TABLE 22 (CONTINUED) 70
  • TABLE 22 (CONTINUED) 71
  • TABLE 22 (CONTINUED) 72
  • TABLE 22 (CONTINUED) 73
  • TABLE 22 (CONTINUED) 74
  • TABLE 22 (CONTINUED) 75
  • TABLE 22 (CONTINUED) 76
  • TABLE 22 (CONTINUED) 77
  • TABLE 23 BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH EXPECTED FDA-APPROVED COMMERCIALIZATION, THROUGH 2013 77
  • TABLE 23 (CONTINUED) 78

Chapter-5: COMPANY PROFILES 58

• ADVANCED LIFE SCIENCES 79
• ARTECEF B.V. 79
• AMERICAN ORIENTAL BIOENGINEERING 80
• ANALYTICON DISCOVERY GMBH 81
• AVESTHAGEN, LTD. 81
• BAYER SCHERING 82
• BIONUMERIK PHARMACEUTICALS, INC. 83
• BIONOVO, INC. 83
• BIONOVO, INC. (CONTINUED) 84
• BOEHRINGER INGELHEIM 85
• PHARMATON SA 85
• BRISTOL MYERS SQUIBB 86
• CARDAX PHARMACEUTICALS 87
• CHONG KUN DANG PHARMACEUTICAL CORPORATION 88
• CUBIST PHARMACEUTICALS, INC. 88
• CURAPHARM, INC. 89
• EISAI, INC. 90
• EKOMED, LLC 91
• ELI LILLY 91
• FYTOKEM PRODUCTS, INC. 92
• GALAPAGOS NV 93
• GLAXOSMITHKLINE 94
• GLOBAL PHARMATECH, INC. 95
• GW PHARMACEUTICALS, PLC 96
• HETEROGENEITY, LLC 96
• INDENA 97
• INDENA (CONTINUED) 98
• JOHNSON & JOHNSON 99
• LIFEPHARMS, INC. 100
• LEO PHARMA 101
• LUPIN, LTD. 102
• LUPIN PHARMACEUTICALS, INC. 102
• MADAUS GMBH 102
• MERA PHARMACEUTICALS, INC. 103
• MERIDIAN MEDICAL TECHNOLOGIES, INC. 103
• KING PHARMACEUTICALS, INC. (PARENT COMPANY) 103
• MERLION PHARMACEUTICALS 104
• MEDIGENE 105
• MEDIGENE, INC. 105
  • TABLE 24 MEDIGENE BOTANICAL PIPELINE 106
• MERCK & CO., INC. 107
• MICROBIO 107
• NAPO PHARMACEUTICALS, INC. 108
• NEUROGESX, INC. 108
• NOVARTIS INTERNATIONAL AG 109
• PANACOS 110
• PHYTOMEDICAL TECHNOLOGIES 111
• PHYTOMEDICS, INC. 111
• PHYTOMEDICS, INC. (CONTINUED) 112
• PFIZER 113
• POLYPHENON PHARMA 114
• POLYPHENON PHARMA (CONTINUED) 115
• PHYNOVA 116
  • TABLE 25 PHYNOVA PIPELINE 117
• PHYTOCEUTICA, INC. 117
• PHYTOMYCO RESEARCH CORP. 118
• PHYTOPHARM, PLC 119
• PIRAMAL ENTERPRISES, LTD. 120
• PUNISYN PHARMACEUTICALS, LTD. 120
• RANBAXY LABORATORIES, LTD. 121
• SANOFI-AVENTIS 121
• SCHWABE PHARMACEUTICALS 122
• SEQUOIA SCIENCES, INC. 123
• SIRTRIS 123
• SOLVAY PHARMACEUTICALS 124
• SUNTEN PHYTOTECH CO., LTD. 124
  • TABLE 26 SUNTECH PHYTOTECH PIPELINE 125
• TASLY PHARMACEUTICALS, INC. 125
• TCM BIOTECH INTERNATIONAL CORP. 126
• VEDIC LIFESCIENCES PVT., LTD. 127
• YAUPON THERAPEUTICS 127
• WYETH PHARMACEUTICALS 128
• ZHEJIANG KANGLAITE GROUP CO, LTD. 129
• ZHEJIANG KANGLAITE ... (CONTINUED) 130

• APPENDIX 131
  • TABLE 27 PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONS 131
  • TABLE 27 (CONTINUED) 132
  • TABLE 27 (CONTINUED) 133
  • TABLE 27 (CONTINUED) 134
  • TABLE 27 (CONTINUED) 135
  • TABLE 28 USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRY 135
  • TABLE 28 (CONTINUED) 136

Related Reports